# Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors Canonical URL: https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-appoints-josh-lehrer-to-its-board-of-directors-6c29e5a6 Ticker: FULC Company: Fulcrum Therapeutics Source: Fulcrum Therapeutics Published: 2026-04-27 10:55 EST ## Summary Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ: FULC), a clinical-stage biopharmaceutical company... ## Article Body Fulcrum Therapeutics, Inc. ® (Fulcrum) (NASDAQ: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules that improve the lives of patients with rare hematological disorders, today announced that Josh Lehrer, M.D., M.Phil., FACC, has been appointed to its Board of Directors as an independent director. Dr. Lehrer is a physician-scientist and biotechnology executive with more than two decades of clinical development experience across all stages of drug development. He currently serves as Chief Executive Officer and a member of the board of directors of Marea Therapeutics, a clinical-stage biotechnology company. Previously, Dr. Lehrer served as President and Chief Executive Officer of Graphite Bio, Inc. from April 2020 until September 2023. Prior to that, he was the Chief Medical Officer at Global Blood Therapeutics where he oversaw the development and approval of Oxbryta ® (voxelotor) for the treatment of sickle cell disease. Earlier in his career, Dr. Lehrer held clinical development and business development roles at Genentech. “We are delighted to welcome Josh to Fulcrum’s Board of Directors,” said Alex C. Sapir, President and Chief Executive Officer of Fulcrum Therapeutics. “Josh brings deep expertise in rare disease drug development and a strong track record advancing transformative therapies, including his leadership in the development and approval of Oxbryta for patients with sickle cell disease. His experience will be invaluable as we continue advancing pociredir and our broader benign hematology pipeline.” “I spent more than a decade working to develop new therapies for patients with sickle cell disease, and the need for effective, orally available treatments remains significant,” said Dr. Lehrer. “Fulcrum is advancing a promising approach with pociredir, supported by results from the PIONEER trial, and I look forward to working alongside the board and management team to help bring this therapy forward for patients.” Dr. Lehrer received an A.B. in Biochemical Sciences from Harvard University and a Master of Philosophy in Biological Sciences from the University of Cambridge. He earned his Doctor of Medicine from the University of California, San Francisco and completed his residency in internal medicine at UCSF, followed by postdoctoral fellowship in cardiovascular medicine at Stanford University. About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules that improve the lives of people with rare hematological disorders. The company’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of genetically defined diseases. For more information, visit www.fulcrumtx.com and follow us on X (@FulcrumTx) and LinkedIn. Contact: Kevin Gardner LifeSci Advisors, LLC kgardner@lifesciadvisors.com 617-283-2856 ## Recent Company News - 2026-06-01 20:05 EST — [Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review](https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-announces-discontinuation-of-pociredir-program-in-sickle-ce-a4687a0d) — Source: Fulcrum Therapeutics - 2026-05-08 20:30 EST — [Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c--af9b71b6) — Source: Fulcrum Therapeutics - 2026-04-27 11:00 EST — [Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026](https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-announces-recent-business-highlights-and-financial-results--b3f1692d) — Source: Fulcrum Therapeutics - 2026-04-27 10:55 EST — [Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors](https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-appoints-josh-lehrer-to-its-board-of-directors-6c29e5a6) — Source: Fulcrum Therapeutics - 2026-04-20 12:00 EST — [Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET](https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-to-host-first-quarter-2026-financial-results-conference-cal-42a5e6f1) — Source: Fulcrum Therapeutics ## Related News - 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627) - 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922) - 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c) - 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec) - 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)